Geron Corporation · NASDAQ:GERN
Geron — Q4 2024 Earnings Presentation
17 slides from Geron's earnings presentation, Feb 26, 2025
Slide 1: Q4 and Full Year 2024 Earnings Call
Q4 and Full Year 2024 Earnings Call February 26, 2025
Slide 2: Welcome and Introduction
Welcome and Introduction JOHN SCARLETT, MICHELLE JIM JOSEPH EID, FAYE FELLER, M.D. ROBERTSON ZIEGLER M.D. M.D. Chairman of the Board, Executive Vice President, Executive Vice President, Executive Vice President, Executive Vice President, President and Chief Chief Financial Officer Chief Commercial O
Slide 3: Forward-Looking Statements
Forward-Looking Statements During the course of this presentation and question-and-answer session, there will be forward-looking statements regarding future events, performance, plans, expectations and other projections, including those relating to: • the launch, commercial opportunity and therapeut
Slide 4: Introductory Remarks
Introductory Remarks John Scarlett, M.D. Chairman and Chief Executive Officer 4
Slide 5: Focused on Key Value Drivers in 2025
Focused on Key Value Drivers in 2025 LR-MDS represents a potential blockbuster market opportunity for RYTELO based on high unmet need and significant product differentiation Phase 3 trial in JAKi R/R MF with overall survival (OS) primary endpoint is 80% enrolled; if positive, an approval in this ind
Slide 6: Commercial Updates
Commercial Updates Jim Ziegler EVP, Chief Commercial Officer 6
Slide 7: Q4 2024 Launch Performance
Q4 2024 Launch Performance Launch Broad Payor Encouraging RYTELO Trajectory Coverage Utilization $47.5M Q4 2024 ~80% Across 1L ESA ineligible, net revenue payor coverage 2L and 3L patients (RS+/RS-) as of the end of Q4 2024^ with duration of therapy consistent with IMerge Phase 3* Focused on driving
Slide 8: Large U.S. Market Opportunity with Blockbuster Potential for RYTELO in LR-MDS
Large U.S. Market Opportunity with Blockbuster Potential for RYTELO in LR-MDS Estimated 2025 U.S. RYTELO Total Addressable LR-MDS Patient Population ∼ 16,800 ~15,400 U.S. RYTELO total ∼45% addressable LR-MDS 1L patients expected to progress to 2L patients in 2025 treatment in 2025 ESA Eligible: ~13,
Slide 9: Medical Updates
Medical Updates Joseph Eid, M.D. EVP, Research and Development 9
Slide 10: Clinical Updates
Clinical Updates Faye Feller, M.D. EVP, Chief Medical Officer 10
Slide 11: First Myelofibrosis Trial with Overall Survival Primary Endpoint
First Myelofibrosis Trial with Overall Survival Primary Endpoint Based on Significant Imetelstat Clinical Experience 2015 2021 ONGOING Single Institution Pilot Study Ph 2 Dose Finding Study Pivotal Ph 3 Trial Median OS in 9.4 mg/kg arm more than First and only Phase 3 trial in MF with Basis for Ph2
Slide 12: Part 1 Findings Suggest Tolerability of Imetelstat Combined with Ruxolitinib in Patients with MF
Part 1 Findings Suggest Tolerability of Imetelstat ClinicalTrials.gov Identifier: NCT05371964 Combined with Ruxolitinib in Patients with MF Actively enrolling patients for dose confirmation with imetelstat 9.4mg/kg PART 2: Dose Confirmation & PART 1: Dose Finding Results Presented at ASH 2024 Expans
Slide 13: Financial Results
Financial Results Michelle Robertson EVP, Chief Financial Officer 13
Slide 14: Financial Overview
Financial Overview Cash Balance Net Revenue Operating Expenses ~$502.9M $47.5M $250.7M Cash and marketable Q4 2024 net 2024 total OpEx securities as of 12/31/24 product revenue $76.5M $270M to $285M 2024 net product revenue 2025 expected since product availability OpEx range end-June Expect to reach
Slide 15: Closing Remarks
Closing Remarks John Scarlett, M.D. Chairman and Chief Executive Officer 15
Slide 16: Multiple Opportunities to Fuel Growth in 2025 & Beyond
Multiple Opportunities to Fuel Growth in 2025 & Beyond June 2024 Nov 2024 Q4 2024 2026 2026 FDA approval & Secured up to $375M in $47.5M product Launch in select Initial Results from U.S. launch of non-equity financings revenue EU countries in Part 2 of Ph1 RYTELO in LR-MDS LR-MDS IMproveMF Q3 2024
Slide 17: Thank you!
Thank you! Contact: Investor Relations investor@geron.com 17